56857-97-7 Usage
Uses
Used in Pharmaceutical Industry:
2,4-DICHLORO-3-METHYLQUINOLINE is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a key component in the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2,4-DICHLORO-3-METHYLQUINOLINE serves as a precursor for the production of various agrochemicals, such as pesticides and herbicides. Its chemical properties make it suitable for the creation of effective and targeted agricultural products.
Used in Research and Development:
2,4-DICHLORO-3-METHYLQUINOLINE is utilized in research and development, particularly in the field of medicinal chemistry. Its potential applications in the synthesis of new compounds and the study of their biological activities make it a valuable tool for scientific exploration and innovation.
However, it is crucial to handle 2,4-DICHLORO-3-METHYLQUINOLINE with care due to its toxic and potentially hazardous properties. Proper safety measures and precautions should be taken to minimize risks associated with its use.
Check Digit Verification of cas no
The CAS Registry Mumber 56857-97-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,6,8,5 and 7 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 56857-97:
(7*5)+(6*6)+(5*8)+(4*5)+(3*7)+(2*9)+(1*7)=177
177 % 10 = 7
So 56857-97-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H7Cl2N/c1-6-9(11)7-4-2-3-5-8(7)13-10(6)12/h2-5H,1H3
56857-97-7Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS AND THEIR USES
-
Page/Page column 40, (2011/01/05)
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
